Qiaoqiao Ci

Ms. Qiaoqiao Ci

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in ACS Sensors
Verified
Journal Article
Open access
XZXue Zhao
Xue Zhao
YHYawen He
Yawen He
SSShengjie Shao
Shengjie Shao
QCQiaoqiao Ci
Qiaoqiao Ci
Lin ChenLin Chen
Lin Chen
JCJuhong Chen
Juhong Chen
The highly contagious nature and 100% fatality rate contribute to the ongoing and expanding impact of the African swine fever virus (ASFV), causing significant economic losses worldwide. Herein, we developed a cascaded colorimetric detection using the combination of a CRISPR/Cas14a system, G-quadruplex DNAzyme, and microfluidic paper-based analytical device. This CRISPR/Cas14a-G4 biosensor could detect ASFV as low as 5 copies/μL and differentiate the wild-type and mutated ASFV DNA with 2-nt difference. Moreover, this approach was employed to detect ASFV in porcine plasma. A broad linear detection range was observed, and the limit of detection in spiked porcine plasma was calculated to be as low as 42-85 copies/μL. Our results indicate that the developed paper platform exhibits the advantages of high sensitivity, excellent specificity, and low cost, making it promising for clinical applications in the field of DNA disease detection and suitable for popularization in low-resourced areas.

20 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YBYuanzhi Bian
Yuanzhi Bian
QCQiaoqiao Ci
Qiaoqiao Ci
XLXin Luo
Xin Luo
Chenming ZhangChenming Zhang
Chenming Zhang
Substance use disorders (SUDs) remain a major global health challenge with limited treatment options and high relapse rates. Vaccines that induce drug-sequestering antibodies have shown promise, but their efficacy is hindered by the poor immunogenicity of small-molecule haptens. Adjuvants, substances that enhance immune responses, are critical for overcoming this limitation and improving vaccine efficacy. This review synthesizes over two decades of preclinical and clinical research to guide rational adjuvant design for SUD vaccines. Five major adjuvant classes are examined: aluminum-salt adjuvants, emulsion adjuvants, toll-like receptor (TLR) agonists, protein immunopotentiators, and cytokine modulators. Their physicochemical properties, innate immune activation profiles, and applications in nicotine, stimulant, and opioid vaccines are discussed. Comparative analyses reveal pronounced drug-specific and carrier-specific variability. Case studies illustrate the superior performance of a complementary TLR-agonist pair in a nicotine nanovaccine versus its limited effect in oxycodone vaccines. They also reveal the differential efficacy of an oil-in-water emulsion adjuvant across antigen types. Four principles emerge: (i) no adjuvant is universally optimal; (ii) drug pharmacology influences immune signaling; (iii) adjuvant-carrier compatibility is important; (iv) complementary adjuvant pairings often outperform single agents. These insights support a precision-vaccinology paradigm that tailors adjuvant strategies to each drug class and the delivery vehicle, advancing the development of next-generation SUD vaccines.

5 July 2025 in International Journal of Toxicology
Verified
Journal Article
Closed access
DWDebra Walter
Debra Walter
QCQiaoqiao Ci
Qiaoqiao Ci
HHHe Hu
He Hu
RDRiley DeHority
Riley DeHority
Jonathan HinckleyJonathan Hinckley
Jonathan Hinckley
Chenming ZhangChenming Zhang
Chenming Zhang
A nanoparticle-based immunization strategy offers a promising treatment for opioid use disorder (OUD). This study tested the in vivo safety of subunit keyhole limpet hemocyanin-loaded lipid–PLGA hybrid nanoparticles (sKLH-hNPs) as a nanocarrier for OUD vaccine in adult male BALB/c mice by subcutaneous administration at an effective low dose (60 μg) and a dose 5-fold higher (300 μg), with cohorts of animals (n = 10/group, including controls) observed and evaluated for behavioral changes. At 3, 14, 28, and 56 days after dosing, mice (n = 3/dose) were sacrificed, and serum was collected for evaluation of electrolytes, minerals, proteins, liver function, renal function, and energy metabolism. Histological examination included all critical organs, gastrocnemius muscle, and skin from the site of injection. For behavioral evaluation, home cage, open field, and reflex observations were compared among the groups. Results demonstrated no statistical differences among the groups, with the exception of respirations observed in the home cage (O-RESP) on Day 3 ( P = 0.03). There was no evidence of any effect of the test product on energy (glucose, cholesterol, triglycerides) or mineral metabolism (phosphorus, calcium) and hepatic function (urea nitrogen, albumin, total bilirubin), and no indication that the test agent caused liver injury, cholestasis, muscle damage, or acid-base imbalance. Histological analysis in control and treated mice generally revealed no significant findings, although small areas of hemorrhage, lymphocyte infiltration, and thick areas in the subcutis were noted in a subset of samples from both control and treated animals. These experiments suggest that the nanoparticle-based product would be safe for vaccines treating OUD.

8 April 2026 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ZQZhen Qian
Zhen Qian
TKTom Kasputis
Tom Kasputis
QCQiaoqiao Ci
Qiaoqiao Ci
YBYuanzhi Bian
Yuanzhi Bian
Chenming ZhangChenming Zhang
Chenming Zhang

11 October 2025 in Biomaterials
Verified
Journal Article
Closed access
YBYuanzhi Bian
Yuanzhi Bian
QCQiaoqiao Ci
Qiaoqiao Ci
KRKobra Rostamizadeh
Kobra Rostamizadeh
CMCourtney Marecki
Courtney Marecki
FHFatima A. Hamid
Fatima A. Hamid
Chenming ZhangChenming Zhang
Chenming Zhang